Improvement in MSQoL domain scores was observed in patients with MO (RFR: quarterly 19.6 [1.8], monthly 21.4 [1.8] vs placebo 14.7 [1.9]; RFP: quarterly 17.5 [1.7], monthly 18.4 [1.6] vs placebo 14.2 [1.7]; EF: quarterly 20.2 [2.0], monthly 22.0 [1.9] vs placebo 17.3 [2.0]; Table 2). In the fremanezumab quarterly with MO group, the RFR domain score change from baseline compared with placebo was significant; the RFP and EF domain score changes were not significantly different from placebo (Table 2). All changes from baseline in MSQoL domain scores in the fremanezumab monthly group were significantly different compared with placebo (Table 2). Similarly, in patients without MO, improvements in MSQoL domain scores were observed (RFR: quarterly 21.9 [2.0], monthly 21.6 [2.0] vs placebo 14.5 [1.9]; RFP: quarterly 16.4 [1.7], monthly 14.2 [1.7] vs placebo 10.2 [1.7]; EF: quarterly 22.4 [2.1], monthly 19.7 [2.1] vs placebo 16.7 [2.1]; Table 2). All MSQoL domain scores in the fremanezumab quarterly without MO group were significantly different compared with placebo (Table 2). In the fremanezumab monthly without MO group, RFR and RFP domain score changes from baseline were significant compared with placebo; no significant difference in the EF domain score was observed (Table 2).